FRAXA Research Foundation sits down with Kaerus CEO Robert Ring to discuss the progress of the company's BK channel program, the exciting science behind it, and the therapeutic potential it holds for people with Fragile X syndrome and their families.
The latest advances in Fragile X syndrome research are moving us closer to impactful treatments. Robert H. Ring, CEO of Kaerus Bioscience Ltd. Bioscience, is at the forefront, collaborating with FRAXA to develop BK channel openers—an innovative therapeutic approach targeting the core challenges of Fragile X. These developments have the potential to not only address symptoms of Fragile X but also to impact the broader neurodevelopmental disorder landscape, including autism. With FRAXA's continued support in validating this research, we’re pushing one step closer to transformative treatments. #FragileX #FXResearch #GeneTherapy #Neurodevelopment #ClinicalTrials #InnovationInScience #AutismResearch #ScientificDiscovery #GeneticResearch #PharmaceuticalResearch https://lnkd.in/eNsP_CB6